Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

22 trials with published results (7%)

Research Maturity

120 completed trials (39% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.0%

9 terminated out of 304 trials

Success Rate

93.0%

+6.4% vs benchmark

Late-Stage Pipeline

6%

17 trials in Phase 3/4

Results Transparency

18%

22 of 120 completed with results

Key Signals

22 with results93% success

Data Visualizations

Phase Distribution

200Total
Not Applicable (67)
Early P 1 (30)
P 1 (67)
P 2 (19)
P 3 (8)
P 4 (9)

Trial Status

Completed120
Recruiting75
Unknown43
Not Yet Recruiting31
Terminated9
Withdrawn9

Trial Success Rate

93.0%

Benchmark: 86.6%

Based on 120 completed trials

Clinical Trials (304)

Showing 20 of 20 trials
NCT06948110RecruitingPrimary

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT02422875Enrolling By InvitationPrimary

Comparative Autoantibody and Immunologic Cell Marker Study

NCT07732309Phase 1Not Yet Recruiting

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

NCT05041309Enrolling By Invitation

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT07513181Phase 2Recruiting

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT04902807Completed

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT07122076Early Phase 1RecruitingPrimary

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

NCT06587828CompletedPrimary

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT07699380Phase 2Recruiting

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT05678374Terminated

Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

NCT06272084Active Not RecruitingPrimary

Analysis of TPE Treatments With multiFiltratePRO

NCT07729826Phase 2Not Yet Recruiting

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

NCT07040774Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

NCT07802665Not Yet Recruiting

Capillary Sampling in Clinical Populations Undergoing Monitoring

NCT02682511Phase 2Active Not Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT06435897Phase 1Not Yet RecruitingPrimary

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

NCT05459870Phase 1Not Yet RecruitingPrimary

CAR-T Cells Targeting Autoimmune Diseases

NCT07784400Not Yet RecruitingPrimary

Inflammation, Autoimmunity and Healthy Ageing in Menopause Transition. An Observational, Cross-sectional Study

NCT06575426Phase 1Recruiting

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT07778446Phase 1Not Yet RecruitingPrimary

A Study to Test CRT-402 in Refractory Autoimmune Disease

Scroll to load more

Research Network

Activity Timeline